Ohr Pharmaceutical is a pharmaceutical company focused on the clinical development of new drugs to address underserved therapeutic needs in markets that are large and growing. The company is currently focused on two lead compounds: Squalamine Eye Drops for treating the wet form of age-related macular degeneration, and OHR/AVR118 for treating cancer cachexia – both of which are currently being investigated in clinical Phase II trials. For more information, visit the company’s Web site at www.ohrpharmaceutical.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: